4.20, 2010
R&D
UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial
10.05, 2009
R&D
UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501.
2.13, 2009
R&D
UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting.
1.15, 2009
R&D
UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials.
10.01, 2008
R&D
UMN-02 pharmacological study results published in the Journal of Pharmacology and Experimental Therapeutics.
6.18, 2008
R&D
UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.
6.10, 2008
R&D
UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.
5.19, 2008
R&D
UMN Pharma presents at DIGESTIVE DESEASE WEEK 2008 in San Diego, California.
4.10, 2008
R&D
UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine.
10.27, 2007
R&D
The results of a pharmacological study on UMN-02 published in the Journal of Pharmacological Sciences.
10.26, 2007
R&D
UMN Pharma is awarded the research fund "Potentiality Verification Stage" sponsored by Japan Science and Technology Agency.
4.17, 2007
R&D
UMN Pharma makes presentation at the annual meeting of the American Association for Cancer Research (AACR) held in Los Angeles, California in 2007.
4.11, 2007
R&D
The result of a clinical study of FluBlĂk (UMN-05) in the US is published in JAMA (The Journal of The American Medical Association).
3.15, 2007
R&D
UMN Pharma makes a presentation at the annual meeting of the Japanese Pharmacological Sciences held in Nagoya in 2007.
